All‐cause mortality
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).
1 finding from 1 review
Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
1 finding from 1 review
Diarrhoea · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).
1 finding from 1 review
FVC · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).
1 finding from 1 review
Z score BMI · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes growth and nutrition: BMI SD score compared with placebo (very low certainty).
1 finding from 1 review
Biochemical markers of essential fatty acid status: EPA and DHA % content of neutrophil membrane · adults and children with cystic fibrosis
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review